Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02181634||Active, not recruiting||Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma||
||Other / Industry||
||74||All||18 Years and older (Adult, Senior)||NCT02181634||PrE0204
|PrE0204||December 9, 2014||September 24, 2016||March 2018||July 4, 2014||July 11, 2017||